Last reviewed · How we verify

Braintree Laboratories — Portfolio Competitive Intelligence Brief

Braintree Laboratories pipeline: 4 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PEG3350 PEG3350 marketed Other
FDA approved bowel preparation containing electrolytes FDA approved bowel preparation containing electrolytes marketed
HalfLytely with Bisacodyl Tablets Bowel Prep Kit HalfLytely with Bisacodyl Tablets Bowel Prep Kit marketed
SUPREP Bowel Prep Kit SUPREP Bowel Prep Kit marketed Osmotic laxative Intestinal lumen Metabolic
Magnesium bowel preparation Magnesium bowel preparation phase 3
Visicol Visicol phase 3 Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ahmed M Maged, MD · 1 shared drug class
  2. Amsterdam UMC, location VUmc · 1 shared drug class
  3. Azienda Policlinico Umberto I · 1 shared drug class
  4. Bayer · 1 shared drug class
  5. Benaroya Research Institute · 1 shared drug class
  6. Bo-In Lee · 1 shared drug class
  7. Brooke Army Medical Center · 1 shared drug class
  8. Aboca Spa Societa' Agricola · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Braintree Laboratories:

Cite this brief

Drug Landscape (2026). Braintree Laboratories — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/braintree-laboratories. Accessed 2026-05-16.

Related